NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview
NovaBridge Biosciences <NBP.OQ> expected to post a loss of 13 cents a share - Earnings Preview
NovaBridge Biosciences NBP.OQ NBP.O is expected to show no change in quarterly revenue when it reports results on August 20 for the period ending March 31 2026
LSEG's mean analyst estimate for NovaBridge Biosciences is for a loss of 13 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for NovaBridge Biosciences is $9.00, about 366.3% above its last closing price of $1.93
This summary was machine generated August 18 at 12:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview